Project: Research project

Project Details


The Mayo Clinic through the vehicle of the North Central Cancer Treatment
Group (NCCTG) will serve as primary research base for the following
CCOP's: Alton Ochsner Medical Foundation, Carle Cancer Center, Cedar
Rapids Oncology Project, the Duluth Clinic, Geisinger Clinic nd Medical
Center, Illinois Oncology Research Association, Iowa Oncology Research,
Association Rapid City Regional Oncology Group, St. Luke's Hospitals,
Sioux Community Cancer Consortium, and Toledo. We will also serve as
research base for cancer control protocol activity of non-CCOP
participants and for the multiple CCOP's outside of our group who
contribute to intergroup cancer treatment and cancer control protocols
which we lead. We will cooperate with our affiliated CCOP's in planning
their program and in conducting appropriate continuing education and
workshops. We will provide training and active support for their data
managers and oncology nurses. We will coordinate their multidisciplinary
involvement in clinical cancer research protocols. This will include
evolving and maintaining standard reporting procedures for surgery,
pathology, and radiation therapy. We will hold regular meetings of the
CCOP's for review of ongoing research, planning future research, and for
related professional activities. We will continue the rigid quality
control procedures which have proved so successful in the past, and
upgrade these procedures as indicated. We will constantly monitor CCOP
performance not only by timely review of patient data sheets, pathology
material, operative reports, and radiation therapy port films, but also
by periodic randomly scheduled monitoring site visits. We will work with
each CCOP participant to aid in their maturation as clinical
investigators. We will assist them in developing new protocols for which
they will share leadership and we will work with them in preparing
publications as well as presentations for national and regional meetings.
We will make every effort to provide them with justifiable pride in their
participation in the National Cancer Program. A high priority over this
grant period will be expansion of our control efforts into cancer
prevention with incorporation of associated basic laboratory support.
Effective start/end date9/15/835/31/15


  • Medicine(all)